Houston software development firm Axon is planning its Texas expansion thanks to its recent acquisition. Photo courtesy of Axon

For Owen D. Goode, Houstonians have a propensity for never being satisfied — and that's been extremely advantageous for his business.

“There’s this feeling in Houston of not being finished yet that I love,” says Goode. “Nobody is every fully satisfied in the best possible way. Nobody is sitting back and saying, ‘This is the best we could have done.’”

Goode, formerly the CEO of Axon, comes from an aviation background that includes operating as both pilot and mechanic. He now uses those skillsets in a very different world—helping to lead a company that focuses on system transformation. Axon, which was founded in 2017 was a boutique software firm focused on cloud engineering and data engineering.

This January, a larger company, Zaelot, led by CEO Jeff Lombard, acquired Axon. Zaelot is a global, software firm with a presence in 14 countries, mostly focused in the United States, Uruguay, and Iceland.

“Together we have a strong suite of offerings across a wide variety of domains including full-stack development, cloud/data engineering, design, staff augmentation, project management, and software architecture. We also have experience in multiple domains, including health care, aviation, defense, finance, and startups,” says Goode.

To the layman, this sounds impressive—and complicated—but what does Zaelot, actually do? Asked to explain at a kindergarten level, Goode says, “We take old code and make it less bad.”

With the motto, “Solve Today, Build Tomorrow,” Goode has worked with companies such as a major international airline to clean up its back end. Using a real estate analogy, Goode says that he and his team transform brownfield development environments (“a half-finished building that’s messy and there’s sewage everywhere”) into greenfield ones. It’s essentially a fresh start for sites that have become muddled over years of neglect.

“Health care is notoriously bad for that,” Goode says, though he is unable to disclose specific past or present clients.

Thanks to the merger with Zaelot, Goode and his team are now poised for rapid growth. Becoming part of a 100-person multinational company has now unlocked capital that Axon had never seen before. Goode promises rapid expansion in Texas, beginning in Houston in the next six months to a year. The executive—now Zaelot’s executive vice president—is already a well-known face on the Houston scene, where he regularly attends Cup of Joey and other Houston community events, such as CodeLaunch.

That growth includes gaining office space and expanding his staff in Space City.

“Zaelot's claim to fame is an extreme focus on employee satisfaction, with a 94 percent retention rate,” he says.

It’s his goal to keep those numbers up by serving the people who work for and with the company and treating them as human beings with families, not interchangeable parts. Next on the horizon, Goode says he and his team will be hiring sales and technical account management positions.

Though Zaelot’s staff is distributed around the world, Goode says Houston will always be home base for him. “It’s a literal launchpad that we’re continuing to grow off of,” he says. “I’m a big believer in Texas in general. And I’m just excited to see what happens.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.

UH lab using mixed reality to optimize designs for the Moon and Mars

hi, tech

University of Houston researchers and students are bringing multiple realities together to help improve the design process for crewed space missions.

Helmed by Vittorio Netti, a researcher for UH and a space architect, the university has launched an XR Lab within the University of Houston architecture building. The lab allows researchers to combine mixed reality (MR), virtual reality (VR), augmented reality (AR) and extended reality (XR) to "blend the physical and digital worlds" to give designers a better understanding of life in space, according to a release from UH.

In the lab researchers can wear MY space suits and goggles, take a VR space walk, or feel what it's like to float to the International Space Station with the help of XR and a crane.

The area in which the researchers conduct this work is known as the "cage" and was developed during a six-month research and design study of lunar surface architecture sponsored by Boeing, which aimed to learn more about the design of a lunar terrain vehicle and a small lunar habitat.

The work is part of UH's Sasakawa International Center of Space Architecture (SICSA), which is led by Olga Bannova, a research associate professor and director of the space architecture graduate program at UH.

She says work like this will drastically cut down research and development time when designing space structures.

“These technologies should be harnessed to mitigate the dependency on physical prototyping of assets and help optimize the design process, drastically reducing research-and-development time and providing a higher level of immersion,” Bannova said in a statement.

Today the research team is shifting its focus on designing for a Mars landing. In the future, they aim to demonstrate and test the system for habitats designed for both lunar and Martian surfaces. They are also working with Boeing to test designs in microgravity, or zero gravity, which exists inside the International Space Station.

Mixed Reality Raising the Bar for Space Architecture on the Moon and MarsStep into this 'Cage' at the University of Houston where physical and digital worlds are merged, allowing students to see and ...